CN104546825A - Medical application of galangin - Google Patents
Medical application of galangin Download PDFInfo
- Publication number
- CN104546825A CN104546825A CN201410857256.4A CN201410857256A CN104546825A CN 104546825 A CN104546825 A CN 104546825A CN 201410857256 A CN201410857256 A CN 201410857256A CN 104546825 A CN104546825 A CN 104546825A
- Authority
- CN
- China
- Prior art keywords
- galangin
- mpp
- present
- parkinsonian
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of medicines, in particular to medical application of galangin and a pharmaceutical composition of the galangin. The galangin provided by the invention can be used for preparing a medicine or a health product for preventing and curing a Parkinson's disease.
Description
Technical field
The present invention relates to Medicines and Health Product field, particularly relate to a kind of medical usage and pharmaceutical composition thereof of galangin.
Background technology
Parkinson disease (Parkinson's disease, PD), have another name called paralysis agitans, are mainly in middle-aged and elderly people, are the common neurodegenerative diseases of a class.Infer itself and brain bottom substrate core and black substance brain cell fast degradation, cannot produce enough neural guidance dopamine strengthens relevant with choline effect, its pathological characteristic is the handicapped chronic degenerative sexual maladjustment of central nervous system's extrapyramidal system, drops to key feature with substantia nigra of midbrain compact part dopaminergic neuron Progressive symmetric erythrokeratodermia degeneration disappearance, striatal dopamine energy level.Different from parkinson disease, stages alzheimer's disease (AD) i.e. senile dementia is a kind of persistence higher nerve functional activity obstacle, it is the most general origin cause of formation of dementia, its major pathologic features is atrophy of cerebral cortex, and reduces and the formation of senile plaque with amyloid-beta deposition, neurofibrillary tangles, mass memory neuron number.Have difference in essence based on above-mentioned two kinds of neurodegenerative diseases, those skilled in the art generally believes: a kind of medicine can treat AD and can it treat between PD and there is no necessary connection.
Parkinson disease incidence of occult, course advancement is slow, clinical main manifestations is the motor symptomses such as static tremor, bradykinesia, myotonia and posture gait disorder, and some patients can with non-athletic symptoms such as hyposmia, autonomic nervous function imbalance, sleep disorder, cognitive impairments, quality of life is badly damaged, and finally causes losing self care ability.
Current research is thought, parkinson disease are the coefficient results of many factors, after the middle age, to the individuality of environmental toxin susceptible, after touching toxin, because of its function of detoxification obstacle, occur that subclinical black substance damages, and increase the weight of with advancing age, the gradual continuous dead degeneration of dopaminergic neuron, the Parkinsonian clinical symptoms of final appearance.Just find that the false heroin of synthesis (MPTP) is poisonous as far back as Langston, Ballard and Burns in 1984, black substance brain cell can be endangered by selectivity, the mitochondrion of dopamine neuron is poisoned to death, and produce parkinson disease.The Parkinson disease model of inducing with regard to this MPTP is in the industry cycle extensively approved then.In fact, the parkinson disease laboratory animal of MPTP and 6-OH Induced by Dopamine and isolated cells model are also uniquely by the large classical model of industry confessed two in the research of current antiparkinsonism drug.
Treatment parkinson disease, mainly with the signal transduction obstacle that medicine goes supplementary dopamine or treatment to cause because of dopamine deficiency in brain, comprise levodopa amine (usually combining dopa decarboxylase inhibitor or COMT inhibitor), dopamine agonist both at home and abroad at present.Cholinergic antagonist or amantadine have good therapeutic effect on the motor complication such as to tremble in addition.But after Long-term taking medicine, neuron reduces drug susceptibility in brain, the appearance of " unusual fluctuation disease " or " drug effect fluctuation " may be caused.Such as " agent end is worsened " or title " on-off phenomenon ", namely duration of efficacy shortens, before taking medicine next time, just return to the parkinson disease morbid state without drug effect ahead of time, need to adjust dosage frequency, use levodopa controlled release agent instead, DR agonist increase long half-lift or increase MAO-B inhibitor etc. reduce the puzzlement of middle and late stage sufferer to curative effect instability.And except Drug therapy, also operative treatment can be considered, as dark brain stimulation art (DeepBrain Stimulation), pale core cautery (Pallidotomy), duodenum dopamine are inculcated art (DuoDopa) etc. and treated for using the not good patient of effect of drugs.Function treatment, naturopathy and speech therapy etc. can recover holding function for patient and language, function of deglutition are offered help.Reasonable selection medicine and physical therapy can control or alleviate motor complication, prevent insecondary dysfunction, but existing medical skill temporarily can't effect a radical cure parkinson disease.
Summary of the invention
Object of the present invention aims to provide a kind of new medical usage and pharmaceutical composition thereof of galangin.
Specifically, a first aspect of the present invention there is provided galangin or the application in the preparation parkinsonian medicine of control or health product of its pharmaceutically acceptable salt, hydrate or prodrug.
In a preference, described galangin is applied in the preparation of the parkinsonian medicine of control or health product as unique active component.
A second aspect of the present invention there is provided one can prevent and treat parkinsonian pharmaceutical composition, and it comprises galangin or its pharmaceutically acceptable salt, hydrate or the prodrug for the treatment of effective dose.
A third aspect of the present invention there is provided one can prevent and treat parkinsonian health product, and it includes galangin or its pharmaceutically acceptable salt, hydrate or the prodrug of effective amount.
The details of various aspects of the present invention is able to detailed description by chapters and sections subsequently.By hereafter and the description of claim, feature of the present invention, object and advantage will be more obvious.
Accompanying drawing explanation
Fig. 1 galangin is to MPP
+the impact of the SH-SY5Y cell viability of induction
As shown in Figure 1A, cause SH-SY5Y cell survival rate to drop to 58% after MPP+ effect 24h, and after galangin pretreatment 4h, (50,75,100 μMs) obviously suppress MPP
+the cell injury caused, and rely in doses; Morphocytology research finds MPP
+cellular morphology under effect has obvious shrinkage and apoptosis, and galangin and positive drug baicalin then obviously can suppress MPP
+the apoptosis (Figure 1B) caused.
Fig. 2 galangin is to MPP
+the impact for the treatment of S H-SY5Y expression of cellular proteins
As shown in Figure 2,1-4 is respectively blank group, MPP
+processed group, galangin (50 μMs) group, positive drug baicalin (50 μMs) group.Compare with matched group, MPP
+bring out p21 after treatment S H-SY5Y cell and increase the reduction with Bcl-2; And after galangin process, MPP
+the p21 caused increases and is significantly suppressed with the reduction of Bcl-2.
Fig. 3 galangin induces the impact of parkinson mice Substantia Nigra gene expression to MPTP
As shown in Figure 3, compared with blank group, MPTP process significantly can raise the expression of mice Substantia Nigra Caspase 3 (P<0.001) gene, and significantly lowers the expression of TH (P<0.001) gene; Through 100mgkg
-1after galangin process, the expression of mice Substantia Nigra Caspase 3 (P<0.01) gene is significantly lowered, and the expression of TH (P<0.05) gene is significantly raised.
Detailed description of the invention
Appearance part of the present invention is based on so unexpected discovery: galangin has certain protective role to the parkinson mouse model midbrain dopaminergic neuron damage that MPTP induces; MPP can be alleviated
+the apoptosis of induction and cellular morphology change, and the key molecule of Neuron Apoptosis path can be regulated and controled further, namely lower the expression of p21 gene and Caspase 3 gene, raise the expression of the rate-limiting enzyme TH gene of Bcl-2 gene and DA synthesis, so it is expected to be developed as the Parkinsonian medicine of control or health product.
And then a first aspect of the present invention there is provided galangin or the application in the preparation parkinsonian medicine of control or health product of its pharmaceutically acceptable salt, hydrate or prodrug.
Preferably, described galangin is applied in the preparation of the parkinsonian medicine of control or health product as unique active component.
A second aspect of the present invention there is provided one can prevent and treat parkinsonian pharmaceutical composition, and it comprises galangin or its pharmaceutically acceptable salt, hydrate or the prodrug for the treatment of effective dose.
A third aspect of the present invention there is provided one can prevent and treat parkinsonian health product, and it includes galangin or its pharmaceutically acceptable salt, hydrate or the prodrug of effective amount.
As known to persons skilled in the art, galangin of the present invention (3,5,7-trihydroxyflavone) has following general structure:
Molecular formula: C
15h
10o
5molecular weight: 270.2369
The present invention also comprises all accordingly pharmaceutically acceptable salt of above-claimed cpd, hydrate or prodrug.These salt can be formed by part (such as, amido) positively charged in compound and electronegative (such as, the trifluoracetic acid) with opposite-sign; Or formed by part (such as, carboxyl) electronegative in compound and positive charge (such as, sodium, potassium, calcium, magnesium).Compound can contain a nonaromatic double bond, has one or more asymmetric center.So these compounds can exist as racemic mixture, independent enantiomer, independent diastereomer, non-enantiomer mixture, cis or transisomer.All these isomers are all expected.Described " prodrug of galangin " is often referred to a kind of material, after using by suitable method, can carry out metabolism or chemical reaction and be transformed into galangin or its salt in subject.
Galangin of the present invention can be separated and prepare from Radix Astagali; Or bought by commercial sources and obtain, its purity all meets medicinal standard; Or utilize marketable material, obtained by compou nd synthesis method traditional in prior art synthesis.Those of ordinary skill in the art can synthesize compound of the present invention according to existing known technology.The compound of synthesis can be further purified further by modes such as column chromatography, high performance liquid chromatography or crystallizations.
Synthetic chemistry transformation, protection functional group methodology (protect or go protection) are helpful to synthesis application compound, and be technology commonly known in the art, as R.Larock, Comprehensive Organic Transformations, VCHPublishers (1989); T.W.Greene and P.G.M.Wuts, Protective Groups in Organic Synthesis, 3
rded., John Wiley and Sons (1999); L.Fieser and M.Fieser, Fieser and Fieser ' s Reagents for OrganicSynthesis, John Wiley and Sons (1994); And L.Paquette, ed., Encyclopedia of Reagents for OrganicSynthesis, has open in John Wiley and Sons (1995).
So that galangin of the present invention is made medicine.Galangin of the present invention can be used alone or uses with the form of pharmaceutical composition.Pharmaceutical composition comprises galangin of the present invention as active component and pharmaceutically suitable carrier.Preferably, pharmaceutical composition of the present invention contains the galangin of the present invention as active component of 0.1 ~ 99.9% percentage by weight." pharmaceutically suitable carrier " can not destroy the pharmaceutical active of galangin of the present invention, simultaneously its effective dose, and consumption when can play pharmaceutical carrier effect is to human non-toxic.
Described pharmaceutically suitable carrier includes but not limited to: soft phospholipid, aluminium stearate, aluminium oxide, ion exchange material, self-emulsifying drug delivery system, tween or other surfactants, serum albumin, buffer substance are if phosphate, glycine, sorbic acid, water, salt, electrolyte are as sulfate protamine, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, magnesium silicate, satisfied fatty acid partial glyceride mixtures etc.
Other conventional excipient substances are as binding agent (as microcrystalline Cellulose), filler (as starch, glucose, Lactis Anhydrous and lactose beadlet), disintegrating agent (as cross-linked pvp, crosslinked carboxymethyl fecula sodium, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricant (as magnesium stearate) and absorption enhancer, absorption carrier, flavouring agent, sweeting agent, excipient, diluent, wetting agent etc.
Galangin of the present invention and its pharmaceutical composition can by the preparations of this area conventional method and can by intestinal or non-bowel or topical routes.Oral formulations comprises capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.; Non-intestinal drug delivery agent comprises injection etc.; Local administration preparation comprises cream, patch, ointment, spray etc.Be preferably oral formulations.
The route of administration of galangin of the present invention and its pharmaceutical composition can be oral, Sublingual, through muscle or subcutaneous, vein, urethra, vagina etc.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, the usually conveniently conditioned disjunction condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percent, ratio, ratio or number by weight.
Unless otherwise defined, all specialties used in literary composition and scientific words and one skilled in the art the same meaning be familiar with.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The use that better implementation method described in literary composition and material only present a demonstration.
The above-mentioned feature that the present invention mentions, or the feature that embodiment is mentioned can combination in any.All features that patent specification discloses can with any composition forms and use, each feature disclosed in description, anyly can provide identical, alternative characteristics that is impartial or similar object replaces.Therefore apart from special instruction, the feature disclosed is only general example that is impartial or similar features.
Embodiment 1 galangin treats parkinsonian activity research
1.SH-SY5Y cell culture
SH-SY5Y cell culture is in the DMEM culture medium (100UmL containing 10% hyclone
-1penicillin and 100 μ gmL
-1streptomycin), 37 DEG C, 5%CO
2cultivate and subculture in incubator.
2.MTT method detects cytoactive
Take the logarithm trophophase SH-SY5Y cell with 1 × 10
5individual/mL concentration is inoculated in overnight incubation in 96 orifice plates.In experiment after galangin (10,25,50,75,100 μMs) pretreatment 4h, add the MPP of 1mM
+effect 24h.Then every hole adds the MTT solution continuation cultivation 4h of 10 μ L containing 5g/L, and every hole adds 150 μ L DMSO and fully vibrates, and measures the absorbance at 570nm place, quantitative response cell survival rate after blue particle dissolves completely by full-automatic microplate reader.
3.Western blot method detects protein expression
To take the logarithm trophophase SH-SY5Y cell, by 1 × 10
6the concentration of individual/ml is inoculated in overnight incubation in 6 porocyte culture plates.After galangin 50 μMs of pretreatment 4h, add the MPP of 1mM
+effect 24h.After process terminates, abandon culture medium, 4 DEG C of PBS clean 1 time, and every hole adds 100 μ l lysates (inhibitors of phosphatases 1 and 2 containing 1%), on ice after cracking 10min, and 15000rpm, 4 DEG C of centrifugal 15min.Get supernatant, BCA method measures protein concentration.Get 30 μ g samples respectively, carry out SDS-PAGE electrophoresis.After electrophoresis terminates, wet method transferring film 1h, 1h closed by 5% skim milk, respectively 4 DEG C and corresponding primary antibodie (antibody dilution carries out with reference to description) overnight incubation, then 1h is hatched with the goat anti-mouse of HRP labelling or two anti-room temperature of goat antirabbit, finally with the colour developing of ECL-prime test kit, dark place exposure, developing and fixing.
4. animal model foundation and grouping administration
48 C57BL/6 male mices, in 12 week age, are divided into 4 groups at random, often organize 12, are respectively matched group, model group, galangin administration group (100mgkg
-1) and positive drug madopar group (50mgkg
-1).Continuous gavage 15 days, 1h lumbar injection MPTP 30mgkg before starting gavage in the 11st day
-1(matched group gives equal-volume normal saline), continuous 5 days, last administration was put to death one day after, is drawn materials.
5. real-time quantitative PCR gene expression detection
Total serum IgE is extracted from mice Substantia Nigra, Nanodrop protein nucleic acid analysis-e/or determining RNA concentration by Trizol method.Get 2 μ g total serum IgE, Reverse Transcription box (Thermo) is reversed into cDNA.By above-mentioned transcription product cDNA, use ddH
2o presses as template after 1:5 dilution proportion, and carry out real-time quantitative PCR reaction, detect TH and Caspase3 gene expression in Substantia Nigra, reference gene selects GAPDH, and primer sequence is as shown in table 1.PCR reaction condition is as follows: after 95 DEG C of denaturation 30sec, carries out 95 DEG C of 5sec degeneration, 60 DEG C of 30sec annealing, totally 40 circulations.
Table 1 mice PCR primer sequence
Result:
1. galangin is to MPP
+the impact of the SH-SY5Y cell viability of induction
As shown in Figure 1A, cause SH-SY5Y cell survival rate to drop to 58% after MPP+ effect 24h, and after galangin pretreatment 4h, (50,75,100 μMs) obviously suppress MPP
+the cell injury caused, and rely in doses; Morphocytology research finds MPP
+cellular morphology under effect has obvious shrinkage and apoptosis, and galangin and positive drug baicalin then obviously can suppress MPP
+the apoptosis (Figure 1B) caused.
2. galangin is to MPP
+the impact for the treatment of S H-SY5Y expression of cellular proteins
As shown in Figure 2,1-4 is respectively blank group, MPP
+processed group, galangin (50 μMs) group, positive drug baicalin (50 μMs) group.Compare with matched group, MPP
+bring out p21 after treatment S H-SY5Y cell and increase the reduction with Bcl-2; And after galangin process, MPP
+the p21 caused increases and is significantly suppressed with the reduction of Bcl-2.
3. galangin induces the impact of parkinson mice Substantia Nigra gene expression on MPTP
As shown in Figure 3, compared with blank group, MPTP process significantly can raise the expression of mice Substantia Nigra Caspase 3 (P<0.001) gene, and significantly lowers the expression of TH (P<0.001) gene; Through 100mgkg
-1after galangin process, the expression of mice Substantia Nigra Caspase 3 (P<0.01) gene is in harmonious proportion significantly down the expression of TH (P<0.05) gene and significantly raises.
Conclusion:
This research proves that galangin induces the damage of parkinson mouse model dopaminergic neuron to have protective effect to MPTP by experiment; MPP can be alleviated
+the apoptosis of induction and cellular morphology change; And the key molecule of Neuron Apoptosis path can be regulated and controled further, namely lower the expression of p21 gene and Caspase 3 gene, raise the expression of Bcl-2 gene and TH gene.Point out its using value in parkinson disease, be expected to be developed as and prevent and treat Parkinsonian medicine clinically.
Many aspects involved in the present invention have been done and have as above been set forth.It is to be understood, however, that put before not departing from spirit of the present invention, those skilled in the art can carry out equivalent change and modification to it, and described change and modification fall into the coverage of the application's claims equally.
Claims (4)
1. galangin or the application in the preparation parkinsonian medicine of control or health product of its pharmaceutically acceptable salt, hydrate or prodrug.
2. apply as claimed in claim 1, it is characterized in that, described galangin is applied in the preparation of the parkinsonian medicine of control or health product as unique active component.
3. can prevent and treat a parkinsonian pharmaceutical composition, it is characterized in that, it comprises galangin or its pharmaceutically acceptable salt, hydrate or the prodrug for the treatment of effective dose.
4. can prevent and treat parkinsonian health product, it is characterized in that, it includes galangin or its pharmaceutically acceptable salt, hydrate or the prodrug of effective amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410857256.4A CN104546825A (en) | 2014-12-30 | 2014-12-30 | Medical application of galangin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410857256.4A CN104546825A (en) | 2014-12-30 | 2014-12-30 | Medical application of galangin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104546825A true CN104546825A (en) | 2015-04-29 |
Family
ID=53064608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410857256.4A Pending CN104546825A (en) | 2014-12-30 | 2014-12-30 | Medical application of galangin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104546825A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891337A (en) * | 2021-03-26 | 2021-06-04 | 河北医科大学 | Application of galangin and its derivatives in preparing medicine for preventing and treating nervous system diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| CN103200949A (en) * | 2010-08-10 | 2013-07-10 | 香港科技大学 | Composition for treating neurodegenerative disease or neuropathological condition |
-
2014
- 2014-12-30 CN CN201410857256.4A patent/CN104546825A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| CN103200949A (en) * | 2010-08-10 | 2013-07-10 | 香港科技大学 | Composition for treating neurodegenerative disease or neuropathological condition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112891337A (en) * | 2021-03-26 | 2021-06-04 | 河北医科大学 | Application of galangin and its derivatives in preparing medicine for preventing and treating nervous system diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104662007B (en) | Cystathionine gamma lyase (CSE) inhibitor | |
| CN104302634B (en) | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | |
| JP6407864B2 (en) | Cystathionine-γ-lyase (CSE) inhibitor | |
| AU2023233141A1 (en) | Method of treatment with tradipitant | |
| KR20200029547A (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods of use thereof | |
| TWI791507B (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
| JP2020200352A (en) | Methods of treating neurodegenerative disorders in specific patient population | |
| EP3615029A2 (en) | Formulations for extending lifespan and healthspan | |
| JP2015517569A (en) | Pharmaceutical composition for the prevention and treatment of mental disorders, behavioral disorders and cognitive disorders | |
| WO2013129220A1 (en) | Pharmaceutical or food containing peptide | |
| US20140024638A1 (en) | Treatment of cognitive dysfunction in schizophrenia | |
| JP6139650B2 (en) | Compositions, methods and uses for the treatment of neurodegenerative diseases or disorders comprising electromagnetic radiation yeast | |
| RU2464023C2 (en) | Therapeutic agent for treating fibromyalgia | |
| CN104510752A (en) | Medical application of astrapterocarpan | |
| WO2021155633A1 (en) | Use of alkyl resorcinol compound in preparation of drug for preventing or treating alzheimer's disease | |
| CN104546825A (en) | Medical application of galangin | |
| KR102540559B1 (en) | A composition for improving cognitive ability containing lactobacillus acidophilus lm1060 strain as an active ingredient and its use | |
| JP2013032308A (en) | Pharmaceutical composition for treating/preventing depression | |
| WO2023155938A2 (en) | Use of capsular polysaccharide extract of bacteroides fragilis in preparation of drug for preventing and treating alzheimer's disease | |
| EP4037684A1 (en) | Medicinal cognitive treatments | |
| CN104490865A (en) | Medical application of amentoflavone | |
| TW201907925A (en) | Lithium salt of N-substituted glycine acid compound and use thereof | |
| CN104857152A (en) | Drug for restoring gastric ulcer wound surface | |
| Kabeš et al. | Biological correlates of piracetam clinical effects in psychotic patients | |
| Ramdé-Tiendrébéogo et al. | Anti-inflammatory activities of total leaf extracts of Ficus sycomorus L.(Moraceae) used in traditional medicine in the treatment of sickle cell disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |